NCT05132569 - Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions

Myasthenia Gravis

Interventions

DRUG

Tolebrutininb

Pharmaceutical form: Film-coated tablet Route of administration: Oral

DRUG

Placebo

Pharmaceutical form: Film-coated tablet Route of administration: Oral

Trial Locations (22)

6725

Investigational Site Number :3480001, Szeged

7623

Investigational Site Number :3480002, Pécs

20007

Georgetown University-Site Number:8400008, Washington D.C.

20132

Investigational Site Number :3800001, Milan

20133

Investigational Site Number :3800002, Milan

28046

Investigational Site Number :7240005, Madrid

33487

SFM Clinical Research, LLC-Site Number:8400006, Boca Raton

80131

Investigational Site Number :3800004, Napoli

200040

Investigational Site Number :1560001, Shanghai

430030

Investigational Site Number :1560002, Wuhan

610041

Investigational Site Number :1560003, Chengdu

33612-6601

University of South Florida Health- Morsani Center for Advanced Healthcare-Site Number:8400001, Tampa

02115

Harvard Medical School - Brigham and Women's Hospital-Site Number:8400004, Boston

00000

Neurology Center of San Antonio, PA-Site Number:8400009, San Antonio

T6G 2B7

Investigational Site Number :1240004, Edmonton

N6A 5A5

Investigational Site Number :1240003, London

00168

Investigational Site Number :3800003, Roma

252-0392

Investigational Site Number :3920002, Sagamihara-shi

41-800

Investigational Site Number :6160001, Zabrze

08907

Investigational Site Number :7240003, L'Hospitalet de Llobregat

EX2 5DW

Investigational Site Number :8260002, Exeter

L9 7LJ

Investigational Site Number :8260001, Liverpool